Drugs & Aging

, Volume 34, Issue 6, pp 467–477 | Cite as

Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry

  • Ho-Jun Jang
  • Sang-Don Park
  • Hyun Woo Park
  • Jon Suh
  • Pyung Chun Oh
  • Jeonggeun Moon
  • Kyounghoon Lee
  • Woong Chol Kang
  • Sung Woo KwonEmail author
  • Tae-Hoon KimEmail author
Original Research Article



Compared with dual antiplatelet therapy including aspirin and clopidogrel, triple antiplatelet therapy including cilostazol has a mortality benefit in patients with ST-segment elevation myocardial infarction. However, whether the mortality benefit persists in elderly patients is not clear.


From 2007 to 2014, 1278 patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention were retrospectively analyzed. The patients were divided into four groups by age (<75 or ≥75 years; young and elderly, respectively) and antiplatelet strategy (triple or dual antiplatelet therapy). We compared the mortality rates between the triple and dual antiplatelet therapy groups.


There were 1052 (male, 85%; mean age, 56.3 ± 10.4 years) patients in the young group and 241 (male, 52.7%; mean age, 80.3 ± 4.5 years) patients in the elderly group. In the young and elderly groups, 220 (20.9%) and 28 (12.3%) patients were treated with triple antiplatelet therapy. During a 1-year follow-up period, 80 patients died (4.2% in the young group vs. 15.5% in the elderly group). Kaplan–Meier survival analysis revealed that triple antiplatelet therapy was associated with a lower mortality rate in the young group (log-rank, p = 0.005). Although there were more angiographic high-risk patients in the elderly group, similar mortality rates were reported (log-rank, p = 0.803) without increased bleeding rates (1 vs. 3.6% in the elderly group, p = 0.217).


Triple antiplatelet therapy might be a better antiplatelet regimen than dual antiplatelet therapy for patients with ST-segment elevation myocardial infarction. Although this benefit was strong in patients aged <75 years, no definite increase in major bleeding was seen for elderly patients (aged ≥75 years).


Percutaneous Coronary Intervention Clopidogrel Elderly Group Major Adverse Cardiac Event Prasugrel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Author Contributions

This article was written and edited by the authors, who take full responsibility for its content.

Compliance with Ethical Standards


This work was supported by the INHA UNIVERSITY Research Grant (INHA-54729). This work was supported by Grant YH16-03-16 from the Yuhan Corporation, Republic of Korea [5]. This work was supported by the INHA UNIVERSITY Research Grant (INHA-51457) [4].

Conflict of interest

Ho-Jun Jang, Sang-Don Park, Hyun Woo Park, Jon Suh, Pyung Chun Oh, Jeonggeun Moon, Kyounghoon Lee, Woong Chol Kang, Sung Woo Kwon, Tae-Hoon Kim declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.


  1. 1.
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009;119(25):3207–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Niazi AK, Dinicolantonio JJ, Lavie CJ, et al. Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? Cardiology. 2013;126(4):233–43.CrossRefPubMedGoogle Scholar
  4. 4.
    Park SD, Moon J, Kwon SW, et al. Prognostic impact of combined contrast-induced acute kidney injury and hypoxic liver injury in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: results from INTERSTELLAR Registry. PLoS One. 2016;11(7):e0159416.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Moon J, Suh J, Oh PC, et al. Relation of stature to outcomes in Korean patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the INTERSTELLAR Registry). Am J Cardiol. 2016;118(2):177–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Jang HJ, Oh PC, Moon J, et al. Prognostic impact of combined dysglycemia and hypoxic liver injury on admission in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary iIntervention (from the INTERSTELLAR Cohort). Am J Cardiol. 2017;119(8):1179–85.CrossRefPubMedGoogle Scholar
  7. 7.
    Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–55.CrossRefPubMedGoogle Scholar
  8. 8.
    Kim TH, Lee HJ, Jang HJ, et al. Impact of final kissing balloon inflation after simple stent implantation for the treatment of non-left main true coronary bifurcation lesions in patients with acute coronary syndrome. Int J Cardiol. 2014;177(3):907–11.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhou Q, Yu XM, Lin HB, et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J. 2009;9(6):380–94.CrossRefPubMedGoogle Scholar
  10. 10.
    Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J. 2011;75(1):99–105.CrossRefPubMedGoogle Scholar
  11. 11.
    Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75.CrossRefPubMedGoogle Scholar
  14. 14.
    Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J. 2010;159(2):284–91.e1.Google Scholar
  15. 15.
    Ota H, Eto M, Ako J, et al. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol. 2009;53(24):2298–305.CrossRefPubMedGoogle Scholar
  16. 16.
    Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000;35(1 Pt 2):237–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Morishita R. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl. 2005;6(4):41–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen Y, Zhang Y, Tang Y, et al. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin. 2014;30(1):37–49.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen J, Meng H, Xu L, et al. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. J Thromb Thrombolysis. 2015;39(1):23–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100(7):1103–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Galyfos G, Geropapas G, Sigala F, et al. Meta-analysis of studies evaluating the effect of cilostazol on major outcomes after carotid stenting. J Endovasc. 2016;23(1):186–95.CrossRefGoogle Scholar
  22. 22.
    Warner CJ, Greaves SW, Larson RJ, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014;59(6):1607–14.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286(6):708–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.CrossRefPubMedGoogle Scholar
  25. 25.
    Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61(3):498–511.CrossRefPubMedGoogle Scholar
  26. 26.
    Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol. 2006;48(11):2178–85.CrossRefPubMedGoogle Scholar
  27. 27.
    Manickavasagam S, Ye Y, Lin Y, et al. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007;21(5):321–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3–11.CrossRefPubMedGoogle Scholar
  29. 29.
    Yang TH, Jin HY, Choi KN, et al. Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. Int J Cardiol. 2013;168(1):207–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011;57(3):280–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157(4):733–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Jang JS, Jin HY, Seo JS, et al. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology. 2012;122(3):133–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl. 2005;6(4):13–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Park KH, Jeong MH, Lee MG, et al. Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation. Korean Circ J. 2009;39(5):190–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Division of CardiologySejong General HospitalBucheonRepublic of Korea
  2. 2.Department of CardiologyInha University HospitalIncheonRepublic of Korea
  3. 3.Department of CardiologySoon Chun Hyang University Bucheon HospitalBucheonRepublic of Korea
  4. 4.Department of CardiologyGachon University Gil Medical CenterIncheonRepublic of Korea

Personalised recommendations